Global Financial Private Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Global Financial Private Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$245K	Buy	+843	New	+$229K	0.02%	225

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Global Financial Private Capital's VRTX Position: Q2 2020 in Review

Global Financial Private Capital opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2020: 843 shares worth $245K. The stake represents 0.02% of the portfolio and ranks #225 among its holdings.

963 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

Global Financial Private Capital held 843 shares of Vertex Pharmaceuticals worth $245K as of Q2 2020.
Vertex Pharmaceuticals was a new Global Financial Private Capital position in Q2 2020.
Vertex Pharmaceuticals made up 0.02% of Global Financial Private Capital's portfolio in Q2 2020, its #225 holding.
963 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Global Financial Private Capital's 13F filing for Q2 2020, filed 11 Aug 2020.